RAB9A, member RAS oncogene family pseudogene 4Genealiases: []
Q-omics provides the consensus-scored RAB9AP4 profile across patient tissues and cancer cell-line models. RAB9AP4 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, RAB9AP4 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, RAB9AP4 RNA expression shows 1,838 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, THCA, and STAD as cancer lineages where RAB9AP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB9AP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB9AP4 survival associations across molecular data types. RAB9AP4 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB9AP4 RNA expression–survival associations across cancer types. High RAB9AP4 expression shows unfavorable associations in THCA, KIRC, HNSC, LUSC and SKCM, but favorable associations in ESCA. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ESCA as the clearest survival context for RAB9AP4 RNA expression.
This table summarizes RAB9AP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RAB9AP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB9AP4 shows lower tumor expression in THCA. The THCA box plot shows higher RAB9AP4 RNA expression in normal versus tumor tissue (log2 FC = −0.008, t-test p = .047).
This table shows molecular features associated with RAB9AP4 in patient tissues and cancer cell lines. In patient samples, RAB9AP4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
